• Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

    ソース: Nasdaq GlobeNewswire / 30 10 2024 06:00:00   America/Chicago

    TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.  

    Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at IR@chemomab.com.

    About Chemomab Therapeutics Ltd.                                                                                                                 
    Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 activity and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com.

    Contact:

    Media & Investors:        
    Chemomab Therapeutics
    Barbara Lindheim
    Consulting Vice President
    Investor & Public Relations,
    Strategic Communications
    Phone: +1 917-355-9234
    barbara.lindheim@chemomab.com
    IR@chemomab.com


    Primary Logo

シェアする